Shirin Arastu‐Kapur
- Molecular Biology top 10%
- Oncology top 10%
- Hematology top 5%
- Public Health, Environmental and Occupational Health top 5%
- Immunology
- Co-authors
- Christopher J. KirkMark K. BennettMatthew BogyoJanet L. AnderlFrancesco ParlatiKevin D. ShenkJean‐François DubremetzJohn C. Boothroyd
- Topics
- Multiple Myeloma Research and Treatments (13 papers)Ubiquitin and proteasome pathways (11 papers)Peptidase Inhibition and Analysis (10 papers)
- Cited by
- HematologyParasitologyOncology
- Partner nations
- United StatesNetherlandsSlovenia
In The Last Decade
Shirin Arastu‐Kapur
28 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 86
- Molecular Biology 777
- Oncology 390
- Hematology 318
- Public Health, Environmental and Occupational Health 317
- Immunology 147
Countries citing papers authored by Shirin Arastu‐Kapur
This map shows the geographic impact of Shirin Arastu‐Kapur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shirin Arastu‐Kapur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shirin Arastu‐Kapur more than expected).
Fields of papers citing papers by Shirin Arastu‐Kapur
This network shows the impact of papers produced by Shirin Arastu‐Kapur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shirin Arastu‐Kapur. The network helps show where Shirin Arastu‐Kapur may publish in the future.
Co-authorship network of co-authors of Shirin Arastu‐Kapur
This figure shows the co-authorship network connecting the top 25 collaborators of Shirin Arastu‐Kapur. A scholar is included among the top collaborators of Shirin Arastu‐Kapur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shirin Arastu‐Kapur. Shirin Arastu‐Kapur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 79 | |
| 3 | 1 | |
| 4 | 49 | |
| 5 | 87 | |
| 6 | 37 | |
| 7 | 2 | |
| 8 | 1 | |
| 9 | 329 | |
| 10 | 62 | |
| 11 | 1 | |
| 12 | 3 | |
| 13 | 3 | |
| 14 | 201 | |
| 15 | 13 | |
| 16 | 38 | |
| 17 | 76 | |
| 18 | 11 | |
| 19 | 26 | |
| 20 | 35 |
About Shirin Arastu‐Kapur
Shirin Arastu‐Kapur is a scholar working on Hematology, Physiology and Oncology, having authored 28 papers that have together received 1.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (13 papers), Ubiquitin and proteasome pathways (11 papers) and Peptidase Inhibition and Analysis (10 papers). The work is most often cited by research in Hematology (318 citations), Parasitology (136 citations) and Oncology (390 citations). Shirin Arastu‐Kapur has collaborated with scholars based in United States, Netherlands and Slovenia. Frequent co-authors include Christopher J. Kirk, Mark K. Bennett, Matthew Bogyo, Janet L. Anderl, Francesco Parlati, Kevin D. Shenk, Jean‐François Dubremetz, John C. Boothroyd, Tony Muchamuel and David L. Alexander. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.